Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 9INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 94Leukemia, Lymphocytic, Chronic, B-Cell 56Neoplasms 37Recurrence 28Lymphoma, Non-Hodgkin 25Myelodysplastic Syndromes 21Multiple Myeloma 18Leukemia 16Lymphoma, Large B-Cell, Diffuse 11Leukemia, Myelomonocytic, Chronic 10Hematologic Neoplasms 10Lymphoma, Mantle-Cell 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma, Follicular 7Lymphoma, B-Cell, Marginal Zone 6Leukemia, Myeloid 6Lymphoma 5Chromosome 17 deletion 5Lymphoma, B-Cell 4Breast Neoplasms 4Waldenstrom Macroglobulinemia 3Small Cell Lung Carcinoma 3Carcinoma, Non-Small-Cell Lung 3Neuroblastoma 2Neoplasms, Plasma Cell 2Neoplasm Metastasis 2Myeloproliferative Disorders 2Lymphoproliferative Disorders 2Hematologic Diseases 2GATA2 Deficiency 2

Interventions

blinatumomab 5midostaurin 2Azacitidine 2venetoclax 1tisagenlecleucel 1siremadlin 1sabatolimab 1pulrodemstat besilate 1posaconazole 1fludarabine phosphate 1fludarabine 1Zoledronic Acid 1Vitamin D 1N,N-dicyclohexyl-isoborneol-10-sulfonamide 1Midazolam 1Idarubicin 1Drug Therapy 1Daunorubicin 1Cytarabine 1Cyclophosphamide 1Calcium 1CD3 Complex 1Anthracyclines 1AP 1903 reagent 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasm, Residual × venetoclax × Clear all
NCT04748848 2023-03-02

A Safety, Tolerability and Preliminary Efficacy Study of CC-90011 in Combination With Venetoclax and Azacitidine in R/R Acute Myeloid Leukemia and Treatment-naïve Participants Not Eligible for Intensive Therapy

Celgene

Phase 1 Terminated
1 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Leukemia, Myeloid, Acute, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡